Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Active not recruiting 3

Sponsor Class

INDUSTRY 2NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Lymphoma, Follicular 6Lymphoma, Non-Hodgkin 3Lymphoma, Mantle-Cell 3Lymphoma 3Lymphoma, Large B-Cell, Diffuse 2Leukemia, Lymphocytic, Chronic, B-Cell 2Neoplasms 1Lymphoma, B-Cell 1

Interventions

Rituximab 9ibrutinib 6acalabrutinib 6Cyclophosphamide 6zanubrutinib 4venetoclax 4fludarabine phosphate 3fludarabine 3Whole-Body Irradiation 3Methotrexate 3Magnetic Resonance Spectroscopy 3Cytarabine 3Cyclosporine 3CT-P10 3Bendamustine Hydrochloride 3merphos 2dexamethasone acetate 2dexamethasone 21-phosphate 2auricularum 2Vincristine 2Peripheral Blood Stem Cell Transplantation 2Mycophenolic Acid 2Melphalan 2Etoposide 2Doxorubicin 2Dexamethasone 2Calcium Dobesilate 2treosulfan 1pirtobrutinib 1palbociclib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Lymphoma, Mantle-Cell × Bendamustine Hydrochloride × 30 days × Clear all
NCT01415752 2026-06-03

Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma

Eastern Cooperative Oncology Group

Phase 2 Active not recruiting
373 enrolled 14 charts
Lymphoid

Lymphoma, Lymphoma, Mantle-Cell

NCT02972840 2026-06-01

A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

Acerta Pharma BV

Phase 3 Active not recruiting
635 enrolled 1 FDA
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

NCT04002297 2026-05-18

MANGROVE

BeOne Medicines

Phase 3 Active not recruiting
510 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡